Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 424

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 424
---
 Genzyme in 2011 was extinguished during 2023

in accordance with the contractual terms.

T he table below sets forth the maximum amount of contingent consideration payable in respect of already-marketed products:

| December 31, 2024                                                                        |       | Payments due by period |                  |                  |                  |
|:-----------------------------------------------------------------------------------------|------:|-----------------------:|:-----------------|:-----------------|:-----------------|
| (€ million)                                                                              | Total |        Less than1 year | From 1 to3 years | From 3 to5 years | More than5 years |
| Commitments relating to contingent consideration inconnection with business combinations |    72 |                     72 | —                | —                | —                |

The nominal amount of contingent consideration was € 133million as of December 31, 2023 and € 604million as of December 31,

2022 . D.19. Provisions, income tax liabilities and other liabilities

The line item Non current provisions and other non-current liabilities comprises the following:

| (€ million)                      |  2024 |  2023 |  2022 |
| Provisions                       | 5,762 | 5,262 | 5,822 |
| Other non-current liabilities(a) | 2,334 | 2,340 |   519 |
| Total                            | 8,096 | 7,602 | 6,341 |

(a) Includes derivative financial instruments: € 121 million as of December 31, 2024 , € 164million as of December 31, 2023 , € 232million as of December 31,

2022 .

The figure as of December 31, 2024 includes € 2,007 million for the liability in respect of royalties payable to Sobi on net sales of Beyfortus (nirsevimab) in

the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a

proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five

years is € 1,140 million; the nominal value of payments estimated to be due after more than five years is € 2,792 million.

Non-current income tax liabilities are described in Note D.19.4., and other current liabilities in Note D.19.5.

|